Infliximab is a chimeric monoclonal antibody that blocks tumor necrosis factor alpha (TNFα), a key cytokine in chronic inflammatory diseases. By binding to both soluble and transmembrane forms of TNFα, it disrupts pro-inflammatory signaling, reduces cytokine release, limits immune cell migration, and decreases tissue damage caused by inflammation. Its effects have been demonstrated across multiple human cell types, and it also inhibits enzymes that degrade joint and connective tissue. The antibody is highly specific, targeting only infliximab (e.g., Remicade®, Remsima®, Inflectra®) without cross-reactivity to other TNFα inhibitors.
Because biologics like infliximab are complex proteins manufactured in living systems, therapeutic drug monitoring (TDM) is essential to optimize dosage, ensure compliance, prevent drug interactions, and reduce toxicity. With patents for first-generation biologics expiring, biosimilars—highly similar but not identical versions—are being introduced. However, due to differences in manufacturing processes and host cell systems, exact copies cannot be made, and even minor variations may alter immunogenicity. This can trigger immune responses that reduce effectiveness or cause adverse events, making careful monitoring and evaluation critical when using biologics and their biosimilars.
This product is manufactured in Turkey by Matriks Biotek.
| Size | 1 x 96 Well |
| Sensitivity | 0.003 µg/mL |
| Dynamic Range | 0.01 – 1 µg/mL |
| Incubation Time | 70 minutes |
| Sample Type | Serum, Plasma |
| Storage | 2-8°C |